NCT04598295View on ClinicalTrials.gov

SH-DS01 on Fecal Metagenomic Stability

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

October 17, 2022

Study Completion Date

October 26, 2022

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

DS-01

synbiotic

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Seed Health

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT04598295 - SH-DS01 on Fecal Metagenomic Stability | Biotech Hunter | Biotech Hunter